Kissei Pharmaceutical Co. Ltd. (4547) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kissei Pharmaceutical Co. Ltd. (4547:JPX), powered by AI.

Current Price
¥3,900
P/E Ratio
14.2
Market Cap
170.1B
Sector
Healthcare
What is the Kissei Pharmaceutical Co. Ltd. stock price forecast?

Kissei Pharmaceutical Co. Ltd. is currently trading at ¥3,900. View real-time AI analysis on Alpha Lenz.

What is Kissei Pharmaceutical Co. Ltd. insider trading activity?

View the latest insider trading data for Kissei Pharmaceutical Co. Ltd. on Alpha Lenz.

What is Kissei Pharmaceutical Co. Ltd.'s P/E ratio?

Kissei Pharmaceutical Co. Ltd.'s P/E ratio is 14.2.

Kissei Pharmaceutical Co. Ltd.

JPX · 4547
¥3,900-80(-2.01%)Market closedJPX regular session 09:00–15:00 JST
Ask about Kissei Pharmaceutical Co. Ltd.'s future dividend policy...
Alpha Chat Insight

Kissei Pharmaceutical Co. Ltd. trades at a P/E of 14.2 (undervalued) with modest ROE of 5.6%. 3Y revenue CAGR of 10.5% highlights clear growth momentum.

Ask for details

Company Overview

Kissei Pharmaceutical Co. Ltd. is a pharmaceutical company based in Japan focused on developing, manufacturing, and marketing a range of medicinal products. Established in 1946, Kissei is dedicated to improving healthcare solutions and advancing medical care through innovative pharmaceutical treatments. The company’s primary areas of concentration include urology, nephrology, dialysis, and metabolism. Kissei is recognized for its contributions to improving patients' lives with treatments specially designed for these critical areas. It engages in both prescription and over-the-counter medications, ensuring accessibility across diverse healthcare needs. The company collaborates with research institutions to stay at the forefront of medical research, emphasizing new drug development. In the financial market, Kissei Pharmaceutical Co. Ltd. plays a vital role in the health sector, providing investors an opportunity to engage with the growing demand for advanced medical treatments driven by an aging global population and the need for improved therapeutic solutions. Listed on the Tokyo Stock Exchange, the company underlines its commitment to innovation and contributing to global health, underpinning its significance in the pharmaceutical industry.

CEOMr. Mutsuo Kanzawa
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees1,778

Company Statistics

FY 2025

Profile

¥170,117,426,700Market Cap
¥88,330,000,000Revenue
0.00Shares Out
1,778Employees

Margins

49.89%Gross
13.17%EBITDA
6.54%Operating
17.67%Pre-Tax
13.56%Net

Valuation

14.22P/E
0.81P/B
1.93EV/Sales
12.66EV/EBITDA
114.10P/FCF

Growth (CAGR)

10.55%Rev 3Yr
6.91%Rev 5Yr
N/AOp Inc 3Yr
25.47%Op Inc 5Yr
-2.78%Net Inc 3Yr
32.90%Net Inc 5Yr

Returns

4.74%ROA
5.58%ROE
6.19%ROIC

Financial Health

¥25,169,000,000Cash & Cash Equivalents
¥8,765,000,000Net Debt
16.15%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kissei Pharmaceutical Co. Ltd. (ticker: 4547) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,778 employees. Market cap is $170.1B.

The current price is 3,900 with a P/E ratio of 14.22x and P/B of 0.81x.

ROE is 5.58% and operating margin is 6.54%. Annual revenue is $88.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kissei Pharmaceutical Co. Ltd. (4547) Stock Forecast 2026 ¥3,900 — Price, Financials & Analyst Targets | Alpha Lenz